Latest & greatest articles for quetiapine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on quetiapine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on quetiapine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for quetiapine

1. Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial

Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial 30073273 2018 08 03 2168-6238 2018 Aug 01 JAMA psychiatry JAMA Psychiatry Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial. 10.1001/jamapsychiatry.2018.1867 Antipsychotic agents, such as quetiapine fumarate, are frequently overprescribed for indications (...) not supported by clinical evidence, potentially causing harm. To investigate if peer comparison letters targeting high-volume primary care prescribers of quetiapine meaningfully reduce their prescribing. Randomized clinical trial (intent to treat) conducted from 2015 to 2017 of prescribers and their patients nationwide in the Medicare program. The trial targeted the 5055 highest-volume primary care prescribers of quetiapine in 2013 and 2014 (approximately 5% of all primary care prescribers of quetiapine

EvidenceUpdates2018

2. Quetiapine

Quetiapine Top results for quetiapine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for quetiapine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Quetiapine

Quetiapine USE OF QUETIAPINE IN PREGNANCY 0344 892 0909 USE OF QUETIAPINE IN PREGNANCY (Date of issue: January 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Quetiapine is an atypical antipsychotic used in the treatment (...) of schizophrenia, bipolar disorder and other psychoses. The data regarding exposure to quetiapine in human pregnancy are limited, with outcomes for less than 300 pregnancies published. These data do not suggest that quetiapine use in pregnancy is associated with an increased risk of spontaneous abortion or congenital anomaly, however increased risks for both these outcomes have been reported for antipsychotics as a group. No studies have been published which investigated risk of stillbirth/IUD, preterm

UK Teratology Information Service2014

4. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Moteshafi H, Stip E CRD summary The authors concluded (...) of schizophrenia and affective disorders. Searching PubMed, EMBASE and PsycINFO were searched up to 2010 without language restrictions. Search terms were reported. ClinicalTrials.gov was searched. Reference lists of relevant articles were checked for further studies. Study selection Eligible studies were randomised controlled trials (RCTs) that compared side effects of four antipsychotics (quetiapine, risperidone, ziprasidone and aripiprazole) in the treatment of patients (aged 18 to 65 years

DARE.2013

5. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of pharmacological treatments in all phases of bipolar disorder, comparing quetiapine with olanzapine and olanzapine plus lithium as well as with other

NHS Economic Evaluation Database.2013

7. Quetiapine (Seroquel XL) - Add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.

Quetiapine (Seroquel XL) - Add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy. Published 10 October Statement of Advice quetiapine (Seroquel XL®) 50 mg, 150 mg, 200 mg, 300mg 400 mg prolonged-release tablets (No: 744/11) AstraZeneca 9 September 2011 ADVICE: in the absence of a submission from the holder of the marketing authorisation quetiapine (Seroquel XL®) is not recommended for use

Scottish Medicines Consortium2011

8. Quetiapine prolonged release and quetiapine immediate release (Seroquel XL and Seroquel IR) - Treatment of major depressive episodes in bipolar disorder

Quetiapine prolonged release and quetiapine immediate release (Seroquel XL and Seroquel IR) - Treatment of major depressive episodes in bipolar disorder

Scottish Medicines Consortium2011

10. Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials

Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials Cheung G, Stapelberg J CRD summary The authors concluded (...) that, using the Neuropsychiatric Inventory and the Clinical Global Impression of Change scale,quetiapine was statistically more effective than placebo for the behavioural and psychological symptoms of dementia in elderly people; the clinical significance of the effects was questionable. Limitations to the review methods mean that the reliability of the authors' conclusion is unclear. Authors' objectives To evaluate the efficacy of quetiapine for the behavioural and psychological symptoms of dementia

DARE.2011

11. Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline

Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline | Evidence (...) -generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Article Text Therapeutics Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Statistics from

Evidence-Based Mental Health2011

12. Seroquel (quetiapine fumarate)

Seroquel (quetiapine fumarate) Drug Approval Package: Seroquel (quetiapine fumarate) NDA #020639/S-049/S-054 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Seroquel (quetiapine fumarate) Tablets Company: AstraZeneca Pharmaceuticals LP Application No.: 020639/S-049/S-054 Approval Date: 07/08/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

FDA - Drug Approval Package2011

13. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study

Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study 19915454 2010 01 20 2010 02 22 2015 11 19 1530-0293 38 2 2010 Feb Critical care medicine Crit. Care Med. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. 419-27 10.1097/CCM.0b013e3181b9e302 To compare the efficacy and safety (...) of scheduled quetiapine to placebo for the treatment of delirium in critically ill patients requiring as-needed haloperidol. Prospective, randomized, double-blind, placebo-controlled study. Three academic medical centers. Thirty-six adult intensive care unit patients with delirium (Intensive Care Delirium Screening Checklist score > or = 4), tolerating enteral nutrition, and without a complicating neurologic condition. Patients were randomized to receive quetiapine 50 mg every 12 hrs or placebo. Quetiapine

EvidenceUpdates2010

14. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression

Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression Article Text Therapeutics Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression Statistics from Altmetric.com No Altmetric data available for this article. Question Question Are quetiapine

Evidence-Based Mental Health2010

15. High- v low-dose quetiapine in schizophrenia: meta-analysis

High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis Painuly N CRD summary The review concluded that high-dose quetiapine was not superior to low doses in the acute treatment of schizophrenia, both in terms of efficacy and effectiveness. In light of the absence of an assessment of trial quality and the limited follow-up periods of the included trials, the author's (...) conclusion should be interpreted with a degree of caution. Authors' objectives To compare the effectiveness of high-dose and low-dose quetiapine in the acute treatment of schizophrenia. Searching PubMed, EMBASE, PsycINFO, AMED, CINHAL and Social SciSearch (SSCI) were searched to August 2007; search terms were reported. References lists of obtained articles were also searched. Study selection Double-blind, randomised controlled trials (RCTs) of the acute treatment of schizophrenia with fixed doses

DARE.2010

16. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. 20724402 2010 08 20 2010 09 23 2016 12 15 1756-1833 341 2010 Aug 19 BMJ (Clinical research ed.) BMJ Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. c4024 10.1136/bmj.c4024 bmj.c4024 To study rates of relapse (...) with quetiapine (400 mg/day) or placebo and were followed up for the next 12 months or until a relapse occurred. Relapse assessed monthly and defined as re-emergence of psychotic symptoms (delusions, conceptual disorganisation, hallucinations, suspiciousness, and unusual thought content) according to predefined thresholds. 178 patients were randomised (89 to quetiapine and 89 to placebo). The Kaplan-Meier estimate of the risk of relapse at 12 months was 41% (95% confidence interval 29% to 53

BMJ2010 Full Text: Link to full Text with Trip Pro

18. Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia

Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia 19411369 2009 06 02 2009 06 30 2015 11 19 1535-7228 166 6 2009 Jun The American journal of psychiatry Am J Psychiatry Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. 691-701 10.1176/appi.ajp.2009.08040613 The authors compared paliperidone (...) extended-release and quetiapine in patients with recently exacerbated schizophrenia requiring hospitalization. In a 6-week double-blind study, inpatients with a recent exacerbation of schizophrenia were randomly assigned to treatment with paliperidone extended-release, quetiapine, or placebo. A 2-week monotherapy phase was followed by a 4-week additive-therapy phase. Target doses were at the upper end of recommended ranges: paliperidone extended-release, 9 or 12 mg/day, and quetiapine, 600 or 800 mg

EvidenceUpdates2009

19. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis

Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder (...) : results of a Markov model analysis Fajutrao L, Paulsson B, Liu S, Locklear J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of quetiapine added to lithium or valproate

NHS Economic Evaluation Database.2009

20. Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults

Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation All Wales Medicines Strategy Group (AWMSG). Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1509. 2009 Authors' conclusions Quetiapine prolonged-release tablets (Seroquel XL®) are recommended as an option for use within NHS Wales for the treatment of schizophrenia

Health Technology Assessment (HTA) Database.2009